SYRE

Spyre Therapeutics, Inc. SYRE

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$8.51B total
FMR LLC
$1.16B+10.6%
BlackRock, Inc.
$577.66M+17.8%
PERCEPTIVE ADVISORS LLC
$383.48M+14.2%
RTW INVESTMENTS, LP
$377.49M+1.9%
Paradigm Biocapital Advisors LP
$340.98M+96.2%
VANGUARD CAPITAL MANAGEMENT LLC
$306.17M+12.8%
STATE STREET CORP
$271.44M+17.3%
VR Adviser, LLC
$265.05M-19.0%
PRICE T ROWE ASSOCIATES INC /MD/
$262.87M+85.2%
DRIEHAUS CAPITAL MANAGEMENT LLC
$248.51M+0.3%
GEODE CAPITAL MANAGEMENT, LLC
$239.26M+48.9%
VANGUARD PORTFOLIO MANAGEMENT LLC
$206.87M+298.2%
Capital World Investors
$205.57M+247.4%
Jupiter Topco LLC
$195.88M--
TCG Crossover Management, LLC
$168.73M0.0%
TANG CAPITAL MANAGEMENT LLC
$167.99M0.0%
BANK OF AMERICA CORP /DE/
$157.84M+44.8%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$152.91MNew
WELLINGTON MANAGEMENT GROUP LLP
$140.41M-13.3%
GOLDMAN SACHS GROUP INC
$131.22M+447.6%
FRANKLIN RESOURCES INC
$130.77M+66.8%
Remedium Capital Partners, LLC
$129.99M-23.2%
Affinity Asset Advisors, LLC
$113.56M0.0%
JPMORGAN CHASE & CO
$98.87M+11.6%
Holocene Advisors, LP
$90.13MNew
See all 269 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SYRE

Earnings Per Share

13fpro.ai/company/SYRE

Loading ratio trend…

SYRE key financials by period

Reported revenue, net income and operating margin by fiscal year, from Spyre Therapeutics, Inc.'s annual filings on SEC EDGAR.

Spyre Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2023$886.0K$-338.8M—
FY 2022$2.3M$-83.8M—
FY 2021$18.7M$-65.8M—
FY 2018$3.9M$-44.3M—
FY 2017$5.2M$-27.2M—
FY 2016$4.6M$-21.7M—
Source: SYRE filings on SEC EDGAR →

SYRE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Spyre Therapeutics, Inc. (SYRE): stock profile, AI score and financials

Spyre Therapeutics, Inc. (SYRE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SYRE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of SYRE by reported 13-F value include FMR, BlackRock, PERCEPTIVE ADVISORS, based on the most recent SEC filings. SYRE trades on the Nasdaq exchange and files with the SEC under CIK 1636282. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SYRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Spyre Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1636282 →